Verastem, Inc. (VSTM)
8.41
-0.97
(-10.34%)
USD |
NASDAQ |
Nov 06, 16:00
8.31
-0.10
(-1.19%)
After-Hours: 20:00
Verastem Research and Development Expense (Annual) : 114.60M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 114.60M |
| December 31, 2024 | 81.33M |
| December 31, 2023 | 61.36M |
| December 31, 2022 | 50.56M |
| December 31, 2021 | 39.35M |
| December 31, 2020 | 40.88M |
| December 31, 2019 | 45.78M |
| December 31, 2018 | 43.65M |
| Date | Value |
|---|---|
| December 31, 2017 | 46.42M |
| December 31, 2016 | 19.78M |
| December 31, 2015 | 40.56M |
| December 31, 2014 | 35.45M |
| December 31, 2013 | 25.93M |
| December 31, 2012 | 21.71M |
| December 31, 2011 | 9.883M |
| December 31, 2010 | 0.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Cytokinetics, Inc. | 405.90M |
| Inovio Pharmaceuticals, Inc. | 52.79M |
| Rigel Pharmaceuticals, Inc. | 33.30M |
| United Therapeutics Corp. | 550.00M |
| SELLAS Life Sciences Group, Inc. | 16.02M |